MCID: PRP080
MIFTS: 53

Peripheral Artery Disease

Categories: Cardiovascular diseases

Aliases & Classifications for Peripheral Artery Disease

MalaCards integrated aliases for Peripheral Artery Disease:

Name: Peripheral Artery Disease 12 15
Peripheral Arterial Diseases 71
Peripheral Arterial Disease 43

Classifications:



External Ids:

Disease Ontology 12 DOID:0050830
MeSH 43 D058729
UMLS 71 C1704436

Summaries for Peripheral Artery Disease

Disease Ontology : 12 An artery disease that is characterized by build up of plaque in the arteries that carry blood to your head, organs, and limbs.

MalaCards based summary : Peripheral Artery Disease, also known as peripheral arterial diseases, is related to peripheral vascular disease and intermittent claudication, and has symptoms including edema, chest pain and angina pectoris. An important gene associated with Peripheral Artery Disease is CDKN2B-AS1 (CDKN2B Antisense RNA 1), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Nebivolol and Acetaminophen have been mentioned in the context of this disorder. Affiliated tissues include endothelial, heart and kidney, and related phenotypes are cardiovascular system and homeostasis/metabolism

Wikipedia : 74 Peripheral artery disease (PAD) is an abnormal narrowing of arteries other than those that supply the... more...

Related Diseases for Peripheral Artery Disease

Diseases related to Peripheral Artery Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 598)
# Related Disease Score Top Affiliating Genes
1 peripheral vascular disease 33.4 VWF VEGFA VCAM1 SELP NOS3 IL6
2 intermittent claudication 31.8 VWF VEGFA SELP IL6 FGF2 CRP
3 hyperlipoproteinemia, type iii 31.7 APOE APOB APOA1
4 end stage renal disease 31.2 VEGFA NOS3 IL6 CST3 CRP ACE
5 limb ischemia 31.2 VWF VEGFA NOS3 IL6 ICAM1 FGF2
6 arteriosclerosis obliterans 31.1 VCAM1 SELP IL6 ICAM1
7 impotence 31.1 VEGFA NOS3 EDN1 ACE
8 chlamydia 31.1 IL6 CRP CCL2
9 hypercholesterolemia, familial, 1 31.1 PCSK9 NOS3 CRP APOE APOB APOA1
10 ischemia 31.0 VEGFA SELP NOS3 ICAM1 FGF2 EDN1
11 lipid metabolism disorder 31.0 PCSK9 IL6 CRP CCL2 APOE APOB
12 aortic aneurysm 30.9 IL6 CRP CDKN2B-AS1 APOE ACE
13 pulmonary disease, chronic obstructive 30.9 IL6 CRP CCL2 ACE
14 hypertriglyceridemia, familial 30.8 APOE APOB APOA1
15 chronic ulcer of skin 30.8 VEGFA IL6 FGF2 CRP
16 atrial fibrillation 30.7 VWF SELP P2RY12 NOS3 IL6 CRP
17 peripheral nervous system disease 30.7 VEGFA NOS3 IL6 FGF2 CRP CCL2
18 hyperglycemia 30.7 VCAM1 NOS3 IL6 APOB
19 arteries, anomalies of 30.7 VWF VEGFA VCAM1 P2RY12 NOS3 IL6
20 diabetic neuropathy 30.7 VEGFA ICAM1 FGF2 ACE
21 angina pectoris 30.7 NOS3 IL6 EDN1 CRP APOA1 ACE
22 chlamydia pneumonia 30.7 IL6 CRP CCL2 APOE
23 generalized atherosclerosis 30.7 VWF IL6 CRP APOE APOB ACE
24 thrombosis 30.7 VWF VCAM1 SELP P2RY12 NOS3
25 covid-19 30.6 IL6 CRP ACE
26 renal artery disease 30.6 NOS3 CST3 ACE
27 cerebrovascular disease 30.6 VWF VCAM1 SELP IL6 ICAM1 CRP
28 aortic disease 30.6 IL6 CRP APOE ACE
29 renovascular hypertension 30.6 NOS3 EDN1 ACE
30 chronic venous insufficiency 30.6 VEGFA VCAM1 SELP ICAM1 CRP
31 decubitus ulcer 30.6 VEGFA IL6 FGF2 CRP
32 active peptic ulcer disease 30.6 VWF P2RY12 CRP
33 tricuspid valve insufficiency 30.6 EDN1 CRP ACE
34 deficiency anemia 30.6 SELP IL6 CRP ACE
35 glucose intolerance 30.5 IL6 CRP CCL2 APOB APOA1 ACE
36 polyneuropathy 30.5 VEGFA IL6 CRP APOA1 ACE
37 antiphospholipid syndrome 30.5 VWF VCAM1 SELP CRP
38 cerebral atherosclerosis 30.5 CRP APOE APOA1 ACE
39 bone disease 30.5 VEGFA TNFRSF11B IL6 ICAM1 CCL2
40 temporal arteritis 30.5 IL6 CRP CCL2
41 left bundle branch hemiblock 30.5 P2RY12 CRP ACE
42 venous insufficiency 30.4 VWF VEGFA VCAM1 SELP ICAM1 CRP
43 periodontitis, chronic 30.4 TNFRSF11B IL6
44 lipoprotein quantitative trait locus 30.4 VWF VEGFA VCAM1 SELP NOS3 IL6
45 congestive heart failure 30.4 VEGFA NOS3 IL6 EDN1 CRP CDKN2B-AS1
46 atherosclerosis susceptibility 30.4 VWF VEGFA VCAM1 SELP PCSK9 NOS3
47 glomerulonephritis 30.4 VCAM1 ICAM1 CCL2 ACE
48 diabetic polyneuropathy 30.4 VEGFA NOS3 APOB
49 raynaud disease 30.4 EDN1 CRP ACE
50 homocysteinemia 30.3 VWF VCAM1 NOS3 CST3 CRP CCL2

Graphical network of the top 20 diseases related to Peripheral Artery Disease:



Diseases related to Peripheral Artery Disease

Symptoms & Phenotypes for Peripheral Artery Disease

UMLS symptoms related to Peripheral Artery Disease:


edema, chest pain, angina pectoris

MGI Mouse Phenotypes related to Peripheral Artery Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.36 ACE APOA1 APOB APOE CRP CST3
2 homeostasis/metabolism MP:0005376 10.3 ACE APOA1 APOB APOE CRP CST3
3 cellular MP:0005384 10.25 APOA1 APOB APOE CST3 FGF2 ICAM1
4 hematopoietic system MP:0005397 10.18 ACE APOE FGF2 ICAM1 IL6 NOS3
5 immune system MP:0005387 10.13 ACE APOB APOE CCL2 CRP ICAM1
6 mortality/aging MP:0010768 10 ACE APOB APOE CST3 EDN1 FGF2
7 liver/biliary system MP:0005370 9.91 ACE APOA1 APOB APOE IL6 NOS3
8 muscle MP:0005369 9.61 APOB APOE CST3 EDN1 FGF2 ICAM1
9 nervous system MP:0003631 9.36 APOB APOE CST3 EDN1 FGF2 ICAM1

Drugs & Therapeutics for Peripheral Artery Disease

Drugs for Peripheral Artery Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 400)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nebivolol Approved, Investigational Phase 4 99200-09-6, 118457-14-0, 152520-56-4 71301
2
Acetaminophen Approved Phase 4 103-90-2 1983
3
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
4
Ezetimibe Approved Phase 4 163222-33-1 150311
5
Simvastatin Approved Phase 4 79902-63-9 54454
6
Alprostadil Approved, Investigational Phase 4 745-65-3 149351 5280723
7
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
8
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
9
Iloprost Approved, Investigational Phase 4 78919-13-8 6443959
10
Testosterone enanthate Approved Phase 4 315-37-7 9416
11
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
12
Testosterone Approved, Experimental, Investigational Phase 4 58-22-0, 481-30-1 10204 6013
13
Methyltestosterone Approved Phase 4 58-18-4 6010
14
Defibrotide Approved, Investigational Phase 4 83712-60-1
15
Dalteparin Approved Phase 4 9005-49-6
16
Tinzaparin Approved Phase 4 9041-08-1, 9005-49-6 25244225
17
Epoprostenol Approved Phase 4 35121-78-9, 61849-14-7 5282411 5280427
18
Triflusal Approved, Investigational Phase 4 322-79-2
19
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
20
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
21
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
22
Iron Approved, Experimental Phase 4 15438-31-0, 7439-89-6 27284 23925
23
Ramipril Approved Phase 4 87333-19-5 5362129
24
Evolocumab Approved Phase 4 1256937-27-5
25
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
26
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
27
Glimepiride Approved Phase 4 93479-97-1 3476
28
Empagliflozin Approved Phase 4 864070-44-0
29
Nicorandil Approved, Investigational Phase 4 65141-46-0 47528
30
Allopurinol Approved Phase 4 315-30-0 2094
31
Febuxostat Approved Phase 4 144060-53-7 134018
32
Rivaroxaban Approved Phase 4 366789-02-8
33
Verapamil Approved Phase 4 52-53-9 2520
34
Angiotensin II Approved, Investigational Phase 4 4474-91-3, 11128-99-7, 68521-88-0 172198
35
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
36
Metformin Approved Phase 4 657-24-9 14219 4091
37
tannic acid Approved Phase 4 1401-55-4
38
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
39
Atorvastatin Approved Phase 4 134523-00-5 60823
40
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
41
Pravastatin Approved Phase 4 81093-37-0 54687
42
Zinc Approved, Investigational Phase 4 7440-66-6 32051
43
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
44
Insulin glargine Approved Phase 4 160337-95-1
45
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
46
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
47
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
48
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
49
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
50
Calcifediol Approved, Nutraceutical Phase 4 19356-17-3 5283731 6433735

Interventional clinical trials:

(show top 50) (show all 1402)
# Name Status NCT ID Phase Drugs
1 SAFE (Sarpogrelate Anplone in Femoro-popliteal Artery Intervention Efficacy) Study : a Randomized Controlled Trial Unknown status NCT02959606 Phase 4 Sarpogrelate SR 300mg;Clopidogrel
2 Paclitaxel-eluting Balloon Angioplasty With Provisional Use of Nitinol Stent Versus Systematic Implantation of Paclitaxel-eluting Stent for the Treatment of Femoropopliteal de Novo Lesions Unknown status NCT01969630 Phase 4
3 Drug Eluting Balloon in peripherAl inTErvention for Below-The-Knee Arteries With Freeway and Lutonix Unknown status NCT02279784 Phase 4
4 Estimation de la capacité Fonctionnelle à la Marche Par Questionnaire Clinique Chez Les Patients adressés Pour Bilan artériel Des Membres inférieurs Unknown status NCT01424020 Phase 4
5 Randomized Trial of Stenting After Dilation With or Without Paclitaxel Eluting Balloon or Atherectomy in Patients With Symptomatic Peripheral Artery Disease Unknown status NCT00986752 Phase 4
6 Excellence In Peripheral Artery Disease Thrombin Receptor Antagonist Intervention In Claudication Evaluation (XLPAD-TRACE Trial) Unknown status NCT02660866 Phase 4 Placebo + background APT + SMT;Vorapaxar 2.08 mg/d + background APT + SMT.
7 Effects of Nicotinic Acid Plus Simvastatin Versus Simvastatin Alone on Carotid and Femoral Intima-Media Thickness in Patients With Peripheral Artery Disease (NASCIT)-A Randomized Controlled Trial Unknown status NCT00712049 Phase 4 simvastatin;Nicotinic Acid
8 Peripheral Artery Disease in Patients on Maintenance Hemodialysis: Risk Factors and the Effect of FIR Therapy Unknown status NCT01095549 Phase 4
9 Randomized Trial of Paclitaxel Eluting Balloon or Conventional Balloon for Treatment of In-Stent Restenosis of the Superficial Femoral Artery in Patients With Symptomatic Peripheral Artery Disease (ISAR-PEBIS) Unknown status NCT01083394 Phase 4
10 Tailored Strategy for Residual Platelet Activity In Advanced Peripheral Artery Disease: New Optimal Management. Unknown status NCT01627431 Phase 4 Acetylsalicylic acid;Clopidogrel
11 A Multicenter, Therapeutic Used Study to Evaluate the Efficacy and Safety of Pletaal SR Capsule (Cilostazol) in Subjects With Peripheral Arterial Disease Symptom Due to Chronic Occlusive Arterial Disease Unknown status NCT01711333 Phase 4 Pletaal SR capsule
12 Platelets Induced Vasodilation, in Vitro and in Vivo Study in Patients With Arteriopathy and Healthy Subjects. Unknown status NCT00152646 Phase 4 placebo, aspirine, clopidogrel
13 The Cook Zilver PTX Drug-eluting Stent Versus Bypass Surgery for the Treatment The Cook Zilver PTX Drug-eluting Stent Versus Bypass Surgery of Femoropopliteal TASC C&D Lesions Unknown status NCT01952457 Phase 4
14 Paclitaxel Eluting Stent or Exercise for Thigh Atherosclerosis (PESETA) Unknown status NCT02033135 Phase 4
15 A Randomized Controlled Trial Comparing Usual Care With a Multifactorial Intensified Intervention on Cardiovascular Risk Factors in Subjects With Arterial Peripheral Disease With and Without Diabetes. The Taulí Intervention Program (TIP). Unknown status NCT00144937 Phase 4 Stepwise therapy for dyslipidemia, hypertension and diabetes
16 Comparison of Stenting Versus Best Medical Therapy for Treatment of Ostial Renal Artery Stenosis: a Randomized Controlled Trial in Patients With Advanced Atherosclerosis. Unknown status NCT00711984 Phase 4
17 Evaluation of Closed Incision Negative Pressure Device (Prevena) to Prevent Vascular Wound Complications Unknown status NCT02581904 Phase 4
18 Efficacy of Self-Expanding Nitinol S.M.A.R.T CONTROLTM Stent Versus Life Stent For The Atherosclerotic Femoro-Popliteal Arterial Disease : Prospective, Multicenter, Randomized, Controlled Trial (SENS-FP-2 Trial) Unknown status NCT01653600 Phase 4
19 EVALUATION OF THE RELATIONSHIP BETWEEN EFFERVESCENT PARACETAMOL AND BLOOD PRESSURE. CLINICAL TRIAL. Unknown status NCT02514538 Phase 4 Non- effervescent Paracetamol kern;Effervescent paracetamol termalgin
20 Comparative Study of the Effects of Telmisartan and Nebivolol on 24-h Ambulatory Blood Pressure and Arterial Stiffness in Patients With Arterial Hypertension Unknown status NCT02057328 Phase 4 TELMISARTAN;NEBIVOLOL
21 Jetstream NAVITUS™ System Endovascular Therapy Post-market Registry (JET) Completed NCT01436435 Phase 4
22 A Prospective, Single-Arm Study to Evaluate the Effects of the Jetstream G3 System on Calcified Peripheral Vascular Lesions Completed NCT01273623 Phase 4
23 Delivery of Dexamethasone to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization Completed NCT01983449 Phase 4 Dexamethasone Sodium Phosphate Injection, USP
24 A Prospective, Randomized, Multicenter Comparison of Balloon Angioplasty and the Cypher Selecttm + Coronary and Infrapopliteal Stent in the Treatment of Subjects With Ischemic Infrapopliteal Arterial Disease Completed NCT00640770 Phase 4
25 Evaluation of the Use of ACOTEC Drug-Eluting Balloon Litos ® in Below-The-Knee Arteries to Treat Critical Limb Ischemia Completed NCT02563535 Phase 4
26 Cilostazol Enhances the Number and Functions of Circulating Endothelial Progenitor Cells and Collateral Formation Assessed by Dual-energy 128-row CT Angiography Mediated Through Multiple Mechanisms in Patients With Mild-to-moderate PAOD Completed NCT01952756 Phase 4 Cilostazol;Dummy Placebo
27 Evaluation of Cilostazol in Combination With L-Carnitine in Subjects With Intermittent Claudication Completed NCT00822172 Phase 4 cilostazol
28 Intermittent Mechanical Compression For Peripheral Arterial Disease Completed NCT00855673 Phase 4 Control
29 Non-Randomized, Prospective, Multi-center Evaluation of the ABSOLUTE™ .035 Peripheral Self-Expanding Stent System for Occluded or Stenotic Superficial Femoral or Proximal Popliteal Arteries Completed NCT00180505 Phase 4
30 Effect of Eicosapentaenoic Acid (EPA) on Major Cardiovascular Events in Hypercholesterolemic Patients: the Japan EPA Lipid Intervention Study (JELIS) Completed NCT00231738 Phase 4 Eicosapentaenoic acid ethyl ester(EPADEL Capsule 300 TM)
31 The Effects of Ramipril on Clinical Symptoms in Patients With Peripheral Arterial Disease Completed NCT00168467 Phase 4 Ramipril
32 Phase IV Study of Statins for Assess the Long-term Pleiotropic Effect Upon Nitric Oxide and C-Reactive Protein Levels in Patients With Peripheral Arterial Disease Completed NCT01041729 Phase 4 Atorvastatin;Standard Medical Treatment
33 Drug Eluting Balloon in peripherAl inTErvention: the DEBATE SFA Study Completed NCT01556542 Phase 4
34 Paclitaxel-coated Balloons in Femoral Indication to Defeat Restenosis Completed NCT01083030 Phase 4
35 Investigation of the Arterial Effects of the Veinoplus(r) Stimlator Device. Completed NCT01592812 Phase 4
36 Effects of Cilostazol on Vascular Endothelial Growth Factor , Inflammatory and Oxidative Stress Biomarkers in Hemodialysis Patients With Peripheral Vascular Disease. Completed NCT00431249 Phase 4 Cilostazol
37 Intra-individual Efficacy Evaluation of DOTAREM®-Enhanced MRA Compared to GADOVIST®-Enhanced MRA in the Diagnosis of Clinically Significant Abdominal or Lower Limb Arterial Diseases Completed NCT00955617 Phase 4
38 The Jetstream G2 System Post-Market Peripheral Vascular IVUS Study Completed NCT00911417 Phase 4
39 NanoCross BTK, a Prospective, Non-randomized, Multicenter, Controlled Trial Evaluating the Performance of the NanoCrossTM .014 Balloon Catheter in Infrapopliteal Lesions Completed NCT01783600 Phase 4
40 Physician-Initiated Trial Investigating the Efficacy of Endovascular Treatment of Femoropopliteal Arterial Stenotic Disease With the Biotronik Passeo-18 Lux Drug Releasing Balloon and the Biotronik Pulsar-18 Stent (Comparing With 4EVER Trial Results) Completed NCT02211664 Phase 4
41 Efficacy Evaluation of Dotarem®-Enhanced MRA Compared to Gadovist®-Enhanced MRA in the Diagnosis of Clinically Significant Abdominal or Limb Arterial Diseases Completed NCT01026389 Phase 4 Dotarem;Gadovist
42 Effect of Plavix Treatment on NO Production Measured by Laser Doppler Method Referring to Endothelial Function in Patients With Severe Coronary Heart Disease Completed NCT00648453 Phase 4 Clopidogrel (Plavix)
43 BeSmooth Study, a Physician-initiated PMCF Trial Investigating the BeSmooth Peripheral Stent System for the Treatment of Iliac Lesions Completed NCT02690051 Phase 4
44 DURABILITY-POP Study - Physician Initiated Trial Investigating the Efficacy of the Implant of Protégé EverFlex Nitinol Stents in Popliteal Lesions Completed NCT01412450 Phase 4
45 DURABILITY+ : a Prospective, Multi-center, Controlled Study Measuring the Durability in Lesions of the Superficial Femoral Artery of the Protégé Everflex+ Stent Completed NCT01412463 Phase 4
46 The Safety and Efficacy of Cilostazol in Ischemic Stroke Patients With Peripheral Arterial Disease (SPAD Study) Completed NCT01188824 Phase 4 Cilostazol
47 ACE Inhibition; A Potential New Therapy for Peripheral Arterial Disease Completed NCT00681226 Phase 4 Ramipril or matching placebo
48 Femoral Artery In-Stent Restenosis (FAIR) Trial Completed NCT01305070 Phase 4
49 GORE VIABAHN Endoprosthesis Versus Bare Nitinol Stent in the Treatment of Long Lesion (>8cm) Superficial Femoral Artery Occlusive Disease Completed NCT00228384 Phase 4
50 The Effect of Angioplasty in Peripheral Arterial Disease on Endothelial Function Completed NCT00660634 Phase 4

Search NIH Clinical Center for Peripheral Artery Disease

Cochrane evidence based reviews: peripheral arterial disease

Genetic Tests for Peripheral Artery Disease

Anatomical Context for Peripheral Artery Disease

MalaCards organs/tissues related to Peripheral Artery Disease:

40
Endothelial, Heart, Kidney, Bone, Testes, Skin, Bone Marrow

Publications for Peripheral Artery Disease

Articles related to Peripheral Artery Disease:

(show top 50) (show all 5142)
# Title Authors PMID Year
1
Serum osteoprotegerin level is positively associated with peripheral artery disease in patients with peritoneal dialysis. 61
31950864 2020
2
Clinical features and prognosis of patients with spontaneous coronary artery dissection. 61
32245641 2020
3
Association of comorbidities with clinical outcomes in patients after acute myocardial infarction. 61
32566721 2020
4
Multifocal arterial disease: clinical implications and management. 61
32371620 2020
5
Concomitant chronic venous insufficiency in patients with peripheral artery disease: insights from MR angiography. 61
32100090 2020
6
Characteristics of high-cost inpatients with peripheral artery disease. 61
31980246 2020
7
Use of statins in patients with peripheral artery disease. 61
31307839 2020
8
Association of Plasma Marker of Oxidized Lipid with Histologic Plaque Instability in Patients with Peripheral Artery Disease. 61
31706994 2020
9
Association of Circulating Hepatocyte Growth Factor and Risk of Incident Peripheral Artery Disease: The Multi-Ethnic Study of Atherosclerosis. 61
32202143 2020
10
Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and coronary or peripheral artery disease. 61
31549153 2020
11
Preoperative sarcopenia is associated with late mortality after off-pump coronary artery bypass grafting. 61
31995164 2020
12
Endarterectomy for Isolated Atherosclerotic Lesions of the Popliteal Artery. 61
32044342 2020
13
Development of an automated micropipette coating method for drug-coated balloons. 61
31967398 2020
14
Characteristics of patients at initiation of renal replacement therapy - experience of a hemodialysis center. 61
32509001 2020
15
Perioperative Outcomes of Lower Extremity Revascularization for Rest Pain and Tissue Loss. 61
31756416 2020
16
Rates and timing of subsequent amputation after initial minor amputation. 61
31980248 2020
17
Changing the patterns of hospitalized diabetic foot ulcer (DFU) over a 5-year period in a multi-disciplinary setting in Thailand. 61
32571283 2020
18
Feasibility and Safety of the Direct Occluded Vessel Puncture Technique as a New Access Site for Complex Peripheral Artery Occlusive Disease. 61
32565529 2020
19
Mortality and Paclitaxel-Coated Devices: An Individual Patient Data Meta-Analysis. 61
32370548 2020
20
Current and emerging drug treatment strategies for peripheral arterial disease. 61
32558590 2020
21
Contemporary cardiovascular outcomes in Taiwanese patients undergoing endovascular therapy for symptomatic lower extremity peripheral arterial disease. 61
31672435 2020
22
Telephone health coaching with exercise monitoring using wearable activity trackers (TeGeCoach) for improving walking impairment in peripheral artery disease: study protocol for a randomised controlled trial and economic evaluation. 61
32503866 2020
23
Type 2 Diabetes Mellitus and Impact of Heart Failure on Prognosis Compared to Other Cardiovascular Diseases: A Nationwide Study. 61
32571092 2020
24
Epidemiology of peripheral artery disease in Palestine. 61
32452724 2020
25
Alcohol Consumption and Cardiovascular Disease: A Mendelian Randomization Study. 61
32367730 2020
26
Association of Perceived Stress Levels With Long-term Mortality in Patients With Peripheral Artery Disease. 61
32573710 2020
27
Serum Metabolic Signatures of Chronic Limb-Threatening Ischemia in Patients with Peripheral Artery Disease. 61
32560175 2020
28
Premature Atherosclerotic Peripheral Artery Disease: an Underrecognized and Undertreated Disorder with a Rising Global Prevalence. 61
32565142 2020
29
Knowledge of peripheral artery disease: What do the public, healthcare practitioners, and trainees know? 61
32000617 2020
30
Thromboxane A2 Receptors Mediate Chronic Mechanoreflex Sensitization in a Rat Model of Simulated Peripheral Artery Disease. 61
32530751 2020
31
Association between anatomical distribution of symptomatic peripheral artery disease and cerebrovascular disease. 61
31980011 2020
32
Impact of peripheral artery disease on prognosis after myocardial infarction: The J-MINUET study. 61
32532585 2020
33
Use of home negative pressure wound therapy in peripheral artery disease and diabetic limb salvage. 61
31972901 2020
34
Serum apolipoprotein A-I concentration differs in coronary and peripheral artery disease. 61
32491935 2020
35
Bioresorbable Drug-Eluting Scaffold for Peripheral Artery Disease: The Best of Two Worlds or Unnecessary? 61
32513048 2020
36
Impact of Hospital Volume on Clinical Outcomes after Aortoiliac Stenting in Patients with Peripheral Artery Disease. 61
31588072 2020
37
Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland. 61
32519113 2020
38
Axillary TAVR under locoregional anesthesia in a patient with peripheral artery disease. 61
32520454 2020
39
Low serum magnesium as a risk factor for peripheral artery disease in chronic kidney disease: an open verdict. 61
32494818 2020
40
Impact of obesity on walking capacity and cardiovascular parameters in patients with peripheral artery disease: A cross-sectional study. 61
32534655 2020
41
Ideal Cardiovascular Health Metrics on the New Occurrence of Peripheral Artery Disease: A Prospective Cohort Study in Northern China. 61
32541812 2020
42
Association of peripheral artery disease with life-space mobility restriction and mortality in community-dwelling older adults. 61
32081483 2020
43
LDL Apheresis-mediated Endothelial Activation Therapy to Severe-Peripheral Artery Disease (LETS-PAD) Study: Rationale and Study Design. 61
32524727 2020
44
Patient Profiles and Health Status Outcomes for Peripheral Artery Disease in High-Income Countries: A Comparison Between the United States and the Netherlands. 61
32539108 2020
45
Discovery of 318 new risk loci for type 2 diabetes and related vascular outcomes among 1.4 million participants in a multi-ancestry meta-analysis. 61
32541925 2020
46
Prevalence of Subclinical Carotid Atherosclerosis and Role of Cardiovascular Risk Factors in Older Adults: Atherosclerosis and Aging are Not Synonyms. 61
32219668 2020
47
Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation and Peripheral Artery Disease: a Systematic Review and Meta-Analysis. 61
32206988 2020
48
ASIC1a does not play a role in evoking the metabolic component of the exercise pressor reflex in a rat model of peripheral artery disease. 61
32502377 2020
49
Relationship Between Disease Specific Quality of Life Measures, Physical Performance, and Activity in People with Intermittent Claudication Caused by Peripheral Artery Disease. 61
32336621 2020
50
Dose optimization of decellularized skeletal muscle extracellular matrix hydrogels for improving perfusion and subsequent validation in an aged hindlimb ischemia model. 61
32432574 2020

Variations for Peripheral Artery Disease

Expression for Peripheral Artery Disease

Search GEO for disease gene expression data for Peripheral Artery Disease.

Pathways for Peripheral Artery Disease

Pathways related to Peripheral Artery Disease according to GeneCards Suite gene sharing:

(show all 31)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.99 VWF VEGFA VCAM1 TNFRSF11B NOS3 IL6
2
Show member pathways
13.31 VWF VEGFA VCAM1 TNFRSF11B IL6 ICAM1
3
Show member pathways
13.27 VWF VEGFA SELP P2RY12 NOS3 APOB
4
Show member pathways
12.62 VEGFA VCAM1 NOS3 ICAM1 CCL2
5
Show member pathways
12.33 VEGFA VCAM1 NOS3 ICAM1 CCL2
6 12.04 VEGFA VCAM1 IL6 FGF2
7 11.96 SELP IL6 ICAM1 CCL2
8
Show member pathways
11.95 PCSK9 APOE APOB APOA1
9 11.94 VEGFA VCAM1 NOS3 ICAM1 EDN1 CCL2
10 11.9 VEGFA NOS3 IL6 EDN1
11 11.85 VCAM1 IL6 ICAM1 EDN1 CCL2
12
Show member pathways
11.83 IL6 ICAM1 CRP CCL2 APOE APOB
13 11.79 VEGFA IL6 ICAM1 CCL2
14 11.76 VWF NOS3 FGF2 CCL2
15 11.69 VEGFA VCAM1 IL6 ICAM1 FGF2 CCL2
16
Show member pathways
11.58 VEGFA VCAM1 IL6 ICAM1
17 11.56 VEGFA NOS3 EDN1
18 11.56 IL6 FGF2 EDN1 CCL2
19 11.5 IL6 ICAM1 CCL2
20 11.49 VEGFA IL6 FGF2
21 11.46 TNFRSF11B IL6 APOE
22 11.45 VCAM1 NOS3 ICAM1
23 11.42 SELP IL6 ICAM1 APOB
24 11.35 VCAM1 SELP IL6 ICAM1 CCL2
25 11.31 NOS3 IL6 CCL2
26 11.27 CCL2 APOE ACE
27 11.24 VCAM1 IL6 ICAM1 APOA1
28
Show member pathways
11.22 VEGFA EDN1 CRP
29 11.17 VEGFA VCAM1 NOS3 IL6 ICAM1 EDN1
30 11.09 VEGFA NOS3 FGF2
31 10.87 VCAM1 ICAM1 CCL2

GO Terms for Peripheral Artery Disease

Cellular components related to Peripheral Artery Disease according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 cell GO:0005623 10.08 P2RY12 NOS3 IL6 ICAM1 FGF2 EDN1
2 cell surface GO:0009986 10 VEGFA VCAM1 PCSK9 P2RY12 ICAM1 APOA1
3 external side of plasma membrane GO:0009897 9.95 VCAM1 SELP P2RY12 ICAM1 ACE
4 early endosome GO:0005769 9.89 VCAM1 PCSK9 APOE APOB APOA1
5 extracellular region GO:0005576 9.8 VWF VEGFA TNFRSF11B PCSK9 IL6 FGF2
6 endoplasmic reticulum lumen GO:0005788 9.73 PCSK9 IL6 CST3 APOE APOB APOA1
7 high-density lipoprotein particle GO:0034364 9.63 APOE APOB APOA1
8 very-low-density lipoprotein particle GO:0034361 9.61 APOE APOB APOA1
9 endocytic vesicle lumen GO:0071682 9.58 APOE APOB APOA1
10 Weibel-Palade body GO:0033093 9.54 VWF EDN1
11 low-density lipoprotein particle GO:0034362 9.54 APOE APOB APOA1
12 extracellular space GO:0005615 9.53 VEGFA VCAM1 TNFRSF11B SELP PCSK9 IL6
13 discoidal high-density lipoprotein particle GO:0034365 9.51 APOE APOA1
14 chylomicron GO:0042627 9.5 APOE APOB APOA1
15 intermediate-density lipoprotein particle GO:0034363 9.33 APOE APOB APOA1

Biological processes related to Peripheral Artery Disease according to GeneCards Suite gene sharing:

(show all 47)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.02 VEGFA NOS3 IL6 CRP CDKN2B-AS1 APOB
2 response to drug GO:0042493 10 TNFRSF11B ICAM1 EDN1 CST3 APOA1
3 in utero embryonic development GO:0001701 9.99 VEGFA NOS3 EDN1 APOB
4 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.98 ICAM1 FGF2 CCL2 APOE
5 response to hypoxia GO:0001666 9.94 VEGFA ICAM1 EDN1 CST3
6 extracellular matrix organization GO:0030198 9.93 VWF VCAM1 TNFRSF11B ICAM1 FGF2
7 cellular response to tumor necrosis factor GO:0071356 9.91 ICAM1 EDN1 CCL2 APOB
8 post-translational protein modification GO:0043687 9.91 PCSK9 IL6 CST3 APOE APOB APOA1
9 cellular response to interleukin-1 GO:0071347 9.88 ICAM1 EDN1 CCL2
10 steroid metabolic process GO:0008202 9.88 PCSK9 APOE APOB APOA1
11 negative regulation of gene expression GO:0010629 9.88 VEGFA FGF2 EDN1 CDKN2B-AS1 APOE ACE
12 platelet degranulation GO:0002576 9.87 VWF VEGFA SELP APOA1
13 positive regulation of MAP kinase activity GO:0043406 9.85 VEGFA FGF2 EDN1
14 response to lipopolysaccharide GO:0032496 9.85 SELP NOS3 ICAM1 EDN1 APOB
15 cytokine-mediated signaling pathway GO:0019221 9.85 VEGFA VCAM1 IL6 ICAM1 FGF2 CCL2
16 retinoid metabolic process GO:0001523 9.84 APOE APOB APOA1
17 regulation of blood pressure GO:0008217 9.84 NOS3 EDN1 ACE
18 cholesterol homeostasis GO:0042632 9.83 PCSK9 APOE APOB APOA1
19 positive regulation of blood vessel endothelial cell migration GO:0043536 9.81 VEGFA NOS3 FGF2
20 heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules GO:0007157 9.81 VCAM1 SELP ICAM1
21 cholesterol metabolic process GO:0008203 9.81 PCSK9 APOE APOB APOA1
22 intermembrane lipid transfer GO:0120009 9.79 APOE APOB APOA1
23 leukocyte cell-cell adhesion GO:0007159 9.73 VCAM1 SELP ICAM1
24 high-density lipoprotein particle clearance GO:0034384 9.7 APOE APOA1
25 negative regulation of lipid storage GO:0010888 9.7 IL6 CRP
26 chylomicron remnant clearance GO:0034382 9.69 APOE APOB
27 very-low-density lipoprotein particle remodeling GO:0034372 9.69 APOE APOA1
28 positive regulation of cholesterol esterification GO:0010873 9.68 APOE APOA1
29 negative regulation of platelet activation GO:0010544 9.68 NOS3 APOE
30 negative regulation of hydrolase activity GO:0051346 9.68 NOS3 APOA1
31 neutrophil mediated immunity GO:0002446 9.67 IL6 ACE
32 artery morphogenesis GO:0048844 9.67 VEGFA APOE APOB
33 regulation of Cdc42 protein signal transduction GO:0032489 9.66 APOE APOA1
34 very-low-density lipoprotein particle clearance GO:0034447 9.65 APOE APOB
35 negative regulation of cellular protein metabolic process GO:0032269 9.65 EDN1 APOE
36 regulation of systemic arterial blood pressure by endothelin GO:0003100 9.65 NOS3 EDN1
37 cholesterol efflux GO:0033344 9.65 APOE APOB APOA1
38 lipoprotein catabolic process GO:0042159 9.63 APOE APOB
39 cellular protein metabolic process GO:0044267 9.63 PCSK9 IL6 CST3 APOE APOB APOA1
40 membrane to membrane docking GO:0022614 9.62 VCAM1 ICAM1
41 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 9.61 VEGFA ACE
42 positive regulation of phospholipid efflux GO:1902995 9.59 APOE APOA1
43 positive regulation of low-density lipoprotein particle receptor catabolic process GO:0032805 9.58 PCSK9 APOE
44 chylomicron assembly GO:0034378 9.5 APOE APOB APOA1
45 chylomicron remodeling GO:0034371 9.43 APOE APOB APOA1
46 lipoprotein biosynthetic process GO:0042158 9.13 APOE APOB APOA1
47 lipoprotein metabolic process GO:0042157 8.92 PCSK9 APOE APOB APOA1

Molecular functions related to Peripheral Artery Disease according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 integrin binding GO:0005178 9.71 VWF VCAM1 ICAM1 FGF2
2 amyloid-beta binding GO:0001540 9.67 CST3 APOE APOA1
3 heparin binding GO:0008201 9.55 VEGFA SELP FGF2 APOE APOB
4 lipid transporter activity GO:0005319 9.5 APOE APOB APOA1
5 lipoprotein particle binding GO:0071813 9.48 APOE APOA1
6 phosphatidylcholine-sterol O-acyltransferase activator activity GO:0060228 9.46 APOE APOA1
7 very-low-density lipoprotein particle receptor binding GO:0070326 9.43 PCSK9 APOE
8 intermembrane cholesterol transfer activity GO:0120020 9.43 APOE APOB APOA1
9 cytokine activity GO:0005125 9.43 VEGFA TNFRSF11B IL6 FGF2 EDN1 CCL2
10 apolipoprotein receptor binding GO:0034190 9.37 PCSK9 APOA1
11 low-density lipoprotein particle receptor binding GO:0050750 8.92 PCSK9 CRP APOE APOB

Sources for Peripheral Artery Disease

3 CDC